BGI Genomics Co Ltd (300676) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-3.08 Million ≈ $-451.41K USD) by net assets (CN¥9.37 Billion ≈ $1.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BGI Genomics Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
BGI Genomics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BGI Genomics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BGI Genomics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
0.151x |
|
Grupo Aval
NYSE:AVAL
|
0.000x |
|
Tokai Carbon Korea Co. Ltd
KQ:064760
|
0.032x |
|
Remy Cointreau
PA:RCO
|
0.002x |
|
Netcompany Group A/S
CO:NETC
|
0.024x |
|
Pertamina Geothermal Energy
JK:PGEO
|
0.026x |
|
Royce Value Closed Fund
NYSE:RVT
|
0.001x |
|
Nextnav Acquisition Corp
NASDAQ:NN
|
0.405x |
Annual Cash Flow Conversion Efficiency for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of BGI Genomics Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BGI Genomics Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
CN¥-63.21 Million ≈ $-9.25 Million |
-0.007x | -171.13% |
| 2024-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
CN¥95.72 Million ≈ $14.01 Million |
0.010x | -74.73% |
| 2023-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
CN¥408.77 Million ≈ $59.82 Million |
0.041x | +219.10% |
| 2022-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
CN¥130.88 Million ≈ $19.15 Million |
0.013x | -95.12% |
| 2021-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
CN¥2.48 Billion ≈ $362.34 Million |
0.262x | -56.13% |
| 2020-12-31 | CN¥6.03 Billion ≈ $881.76 Million |
CN¥3.60 Billion ≈ $527.19 Million |
0.598x | +1088.56% |
| 2019-12-31 | CN¥4.46 Billion ≈ $652.35 Million |
CN¥224.25 Million ≈ $32.82 Million |
0.050x | +1315.25% |
| 2018-12-31 | CN¥4.13 Billion ≈ $604.67 Million |
CN¥14.69 Million ≈ $2.15 Million |
0.004x | -93.79% |
| 2017-12-31 | CN¥4.26 Billion ≈ $623.07 Million |
CN¥243.66 Million ≈ $35.66 Million |
0.057x | -15.59% |
| 2016-12-31 | CN¥3.45 Billion ≈ $505.22 Million |
CN¥234.07 Million ≈ $34.25 Million |
0.068x | -34.62% |
| 2015-12-31 | CN¥3.17 Billion ≈ $463.80 Million |
CN¥328.68 Million ≈ $48.10 Million |
0.104x | +1961.44% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.45 Million |
CN¥-8.16 Million ≈ $-1.19 Million |
-0.006x | -109.08% |
| 2013-12-31 | CN¥597.94 Million ≈ $87.50 Million |
CN¥36.70 Million ≈ $5.37 Million |
0.061x | -87.27% |
| 2012-12-31 | CN¥150.37 Million ≈ $22.00 Million |
CN¥72.49 Million ≈ $10.61 Million |
0.482x | -- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more